Literature DB >> 12438511

Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting.

Irène Brigger1, Jackie Morizet, Geneviève Aubert, Hélène Chacun, Marie-José Terrier-Lacombe, Patrick Couvreur, Gilles Vassal.   

Abstract

The aim of the present study was to evaluate the tumor accumulation of radiolabeled long-circulating poly(ethylene glycol) (PEG)-coated hexadecylcyanoacrylate nanospheres and non-PEG-coated hexadecylcyanoacrylate nanospheres (used as control), after intravenous injection in Fischer rats bearing intracerebrally well established 9L gliosarcoma. Both types of nanospheres showed an accumulation with a retention effect in the 9L tumor. However, long-circulating nanospheres concentrated 3.1 times higher in the gliosarcoma, compared with non-PEG-coated nanospheres. The tumor-to-brain ratio of pegylated nanospheres was found to be 11, which was in accordance with the ratios reported for other carriers tested for brain tumor targeting such as long-circulating liposomes or labels for magnetic resonance imaging. In addition, a 4- to 8-fold higher accumulation of the PEG-coated carriers was observed in normal brain regions, when compared with control nanospheres. Using a simplified pharmacokinetic model, two different mechanisms were proposed to explain this higher concentration of PEG-coated nanospheres in a tumoral brain. 1) in the 9L tumor, the preferential accumulation of pegylated nanospheres was attributable to their slower plasma clearance, relative to control nanospheres. Diffusion/convection was the proposed mechanism for extravasation of the nanospheres in the 9L interstitium, across the altered blood-brain barrier. 2) In addition, PEG-coated nanospheres displayed an affinity with the brain endothelial cells (normal brain region), which may not be considered as the result of a simple diffusion/convection process. The exact underlying mechanism of such affinity deserves further investigation, since it was observed to be as important as specific interactions described for immunoliposomes with the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438511     DOI: 10.1124/jpet.102.039669

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

1.  Development of transferrin functionalized poly(ethylene glycol)/poly(lactic acid) amphiphilic block copolymeric micelles as a potential delivery system targeting brain glioma.

Authors:  Wei-hua Ren; Jiang Chang; Cheng-hu Yan; Xiao-min Qian; Li-xia Long; Bin He; Xu-bo Yuan; Chun-sheng Kang; Didier Betbeder; Jing Sheng; Pei-yu Pu
Journal:  J Mater Sci Mater Med       Date:  2010-06-10       Impact factor: 3.896

2.  Recent advances in nanotechnology based drug delivery to the brain.

Authors:  Li-Na Lin; Qun Liu; Lei Song; Fang-Fang Liu; Jin-Xiu Sha
Journal:  Cytotechnology       Date:  2010-08-11       Impact factor: 2.058

Review 3.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

4.  A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue.

Authors:  Elizabeth A Nance; Graeme F Woodworth; Kurt A Sailor; Ting-Yu Shih; Qingguo Xu; Ganesh Swaminathan; Dennis Xiang; Charles Eberhart; Justin Hanes
Journal:  Sci Transl Med       Date:  2012-08-29       Impact factor: 17.956

5.  Enhanced brain distribution of modified aspartoacylase.

Authors:  Nitesh K Poddar; Stephen Zano; Reka Natarajan; Bryan Yamamoto; Ronald E Viola
Journal:  Mol Genet Metab       Date:  2014-07-12       Impact factor: 4.797

Review 6.  Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.

Authors:  Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2019-09-14       Impact factor: 12.479

7.  A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles.

Authors:  E Garcia-Garcia; S Gil; K Andrieux; D Desmaële; V Nicolas; F Taran; D Georgin; J P Andreux; F Roux; P Couvreur
Journal:  Cell Mol Life Sci       Date:  2005-06       Impact factor: 9.261

8.  Circumventing tumor resistance to chemotherapy by nanotechnology.

Authors:  Xing-Jie Liang; Chunying Chen; Yuliang Zhao; Paul C Wang
Journal:  Methods Mol Biol       Date:  2010

9.  Ergosterol-loaded poly(lactide-co-glycolide) nanoparticles with enhanced in vitro antitumor activity and oral bioavailability.

Authors:  Hui-Yun Zhang; Caleb Kesse Firempong; Yuan-Wen Wang; Wen-Qian Xu; Miao-Miao Wang; Xia Cao; Yuan Zhu; Shan-Shan Tong; Jiang-Nan Yu; Xi-Ming Xu
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

Review 10.  Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS.

Authors:  Gabriel A Silva
Journal:  BMC Neurosci       Date:  2008-12-10       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.